Molecular Partners Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Molecular Partners Inc. | MOLN - NASDAQ |
$27.14-$27.14 | $21.25 | $20.00 | 3 million ADSs | 6/16/2021 |
| JP Morgan, SVB Leerink, Cowen, RBC Capital | ||||||
Co-Manager(s): Kempen & Co. | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-04-22 Terms Added 2021-06-09 | ||||||
Molecular Partners Inc. Quote & Chart - Click for current quote - MOLN
IPO Boutique aggregates information on public companies and private companies, such as "MOLN" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Molecular Partners Inc. (adapted from Molecular Partners Inc. prospectus):
They are a clinical stage biopharmaceutical company applying our pioneering DARPin® product candidates to treat serious diseases, with a current focus on infectious disease, oncology and ophthalmology.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical stage biopharmaceutical company applying our pioneering DARPin® product candidates to treat serious diseases, with a current focus on infectious disease, oncology and ophthalmology.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "MOLN" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.